Roche's AXELIOS 1 enters next generation DNA sequencing. Can it or rivals unseat Illumina's long-standing market dominance?

With 10 cases in 2025, Guinea worm could be the second disease ever eradicated. Here is what makes disease eradication ...

New therapies in the clinic for bipolar disorder hope to meet unmet needs of efficacy and minimal side effects.

The biggest acquisition deal announced in June was by pharma giant AbbVie. Known for its monoclonal antibodies Humira and Skyrizi, for autoimmune diseases, AbbVie plans to buy Massachusetts-based ...

Artificial intelligence (AI) may be transforming drug discovery, but one of the industry’s biggest problems remains unchanged: much of the biology used to develop new medicines still does not fully ...

Over the past year, a growing number of companies have relaunched under fresh brands, often accompanied by promises of a new chapter, renewed focus, or a transformed business strategy. On the surface, ...

For a long time, neurological drug development has largely focused on the cells that ultimately die or malfunction. Alzheimer’s researchers chased amyloid and tau. Parkinson’s drug development ...

A shift in the European pharma sector’s center of gravity might be underway as Spain continues to build on its reputation for innovative biotechnology and life science. Now ranked third in scientific ...

Atopic dermatitis is a chronic, relapsing inflammatory skin disorder characterized by eczematous lesions and intense itchiness, which can substantially impair an individual’s quality of life. Over the ...

U.K.-based biotech Allergy Therapeutics is focused on diagnosing and developing treatments for allergic disorders, including aluminium-free immunotherapies that have the potential to cure disease. The ...

A significant trend in the cell and gene therapy space is the swing towards in vivo therapies. In vivo, simply put, means inside the body. Cell and gene therapies are often developed ex vivo – outside ...

The life science sector brought about €29.7 billion ($34.41 billion) and €8.9 billion ($10.31 billion) in gross value added in 2024, according to a report by the Portuguese Trade & Investment Agency.